Coriase Hair & Vital
Food supplement declared in France, decision dated 24 January 2025
Coriase Hair & Vital, from GmbH, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Galactomannanes 5,100 mg per day, arginine 500 mg per day, cystéine 450 mg per day, méthionine 225 mg per day, oligo-proanthocyanidines 150 mg per day. None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.
- Brand
- not provided
- Food business operator placing the product on the market
- GmbH
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Powder
- Daily dose
- 15 g
- Directions for use
- Prendre 1 cuillère doseuse de granulé le matin et le soir ou le matin et le midi directement ou mélangé à 1 dl d'eau/de jus de fruits/de jus de légumes ou brassé dans un yaourt.
- Intended populations
- General population
- Not recommended (according to the manufacturer)
- Taking anticoagulants
Declaration 5241, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Cynara scolymus L. | Capitule | Extrait fluide hydroalcoolique | 400 mg |
| Silybum marianum (L.) Gaertn. | Parties aériennes | Extrait sec hydroalcoolique | 20 mg |
| Gentiana lutea L. | Racine | Extrait sec hydroalcoolique | 20 mg |
Substances
| Name | Per day |
|---|---|
| Galactomannanes | 5,100 mg |
| arginine | 500 mg |
| cystéine | 450 mg |
| méthionine | 225 mg |
| oligo-proanthocyanidines | 150 mg |
| quercétine | 100 mg |
| inositol | 20 mg |
Other active ingredients
| Name | Per day |
|---|---|
| Fibres de pomme | not declared |
| Inuline | not declared |
| Ubiquinone | not declared |
| Chlorure de choline | not declared |
| Lysine | not declared |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| D-pantothenate, calcium | Pantothenic acid (vitamin B5) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| D-biotin | Biotin (vitamin B8) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| beta-carotene | β-Carotene | no limit (insufficient data) | no fixed dose |
| calcium carbonate | Calcium | 2,500 mg | 800 mg |
| calcium lactate | Calcium | 2,500 mg | 800 mg |
| Chlorure de chrome | Chromium | no limit (insufficient data) | 25 µg |
| cupric sulphate | Copper | 5,000 µg | 2,000 µg |
| ferrous bisglycinate | Iron | 40 mg (safe level) | 14 mg |
| calcium-L-methylfolate | Folate (vitamin B9) | 1,000 µg | 200 µg |
| potassium iodide | Iodine | 600 µg | 150 µg |
| magnesium salts of citric acid | Magnesium | 250 mg | 300 mg |
| magnesium carbonate | Magnesium | 250 mg | 300 mg |
| manganese gluconate | Manganese | 8 mg (safe level) | 3.5 mg |
| Molybdate de sodium | Molybdenum | 600 µg | 150 µg |
| nicotinamide | Nicotinamide (vitamin B3) | 900 mg | 54 mg |
| potassium salts of orthophosphoric acid | Phosphorus | no limit (insufficient data) | 450 mg |
| potassium chloride | Potassium | no limit (insufficient data) | 80 mg |
| sodium selenite | Selenium | 255 µg | 50 µg |
| thiamin hydrochloride | Vitamin B1 (thiamine) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| methylcobalamin | Vitamin B12 | no adverse effect defined | dose annulled by the French Council of State in 2011 |
| riboflavin | Vitamin B2 (riboflavin) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| pyridoxal 5′-phosphate | Vitamin B6 | 12 mg | 2 mg |
| L-ascorbic acid | Vitamin C | no limit (insufficient data) | 180 mg |
| cholecalciferol | Vitamin D | 100 µg (4,000 IU) | 5 µg (200 IU) |
| D-alpha-tocopherol | Vitamin E | 300 mg | 30 mg |
| menaquinone | Vitamin K | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| zinc citrate | Zinc | 25 mg | 15 mg |
Additives
E464, E306, E330, E307, E300, E414, E551, E470b
Other ingredients
Amidon de pomme de terre
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Has the product changed? Photograph the packaging.
Label warnings
Un produit avec OPC ne remplace pas une alimentation à base de fruits et légumes frais. Il est conseillé aux personnes sous traitement anticoagulant de consulter leur médecin avant de consommer des préparations à base de vitamine K.
Regulatory points
None of the rules we check applies to the declared ingredients.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Silybum marianum (L.) Gaertn.
Read the warning, when it applies and the studies cited
MILK THISTLE - SILYBUM MARIANUM
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Brinker 2010; Mills et al. 2006).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills E, Dugoua J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation : An Evidence-Based Approach. London (UK): Taylor and Francis Medical; 2006.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Geier et al. 1990; Mironets et al. 1990).
Sources cited by Health Canada (2)
- Geier J, Fuchs Th, Wahl R. [Anaphylactic shock due to an extract of Silybum marianum in a patient with immediate-type allergy to Kiwi fruit]. Anaphylaktischer Schock durch einen Mariendistel-Extrakt bei Soforttyp-Allergie auf Kiwi. Allergologie 1990;13(10):387-388 (in German).
- Mironets VI, Krasovskaia EA, Polischuk II. [A case of urticaria during carsil treatment]. Vrachebnoe Delo 1990;(7):86-87 (in Russian).
- Gentiana lutea L.
Read the warning, when it applies and the studies cited
Gentian - Gentiana Lutea
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.
Contraindications
Do not use if you are pregnant (Hoffmann 2003; Morimoto et al.1983).
Sources cited by Health Canada (2)
- Hoffmann D. Medical Herbalism. Rochester (VT): Healing Arts Press; 2003.
- Morimoto I, Nozaka T, Watanabe F, Ishino M, Hirose Y, Okitsu T. Mutagenic activities of gentisin and isogentisin from Gentianae radix (Gentianaceae). Mutation Research 1983;116(2):103-117. PubMed
Do not use if you have stomach or duodenal acute inflammation or ulcer (Brinker 2010; ESCOP 2003; Bradley 1992).
Sources cited by Health Canada (2)
- Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 1. Bournemouth (UK): British Herbal Medicine Association; 1992.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Known adverse reactions
When using this product you may experience headaches (ESCOP 2003; Hoffmann 2003; Blumenthal et al. 2000).
Sources cited by Health Canada (3)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- Hoffmann D. Medical Herbalism. Rochester (VT): Healing Arts Press; 2003.
- arginine
Read the warning, when it applies and the studies cited
L-ARGININE
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are pregnant or breastfeeding.
Condition of application: Improvement in exercise capacity in individuals with stable CVD.
Ask a health care practitioner/health care provider/health care professional/doctor/ physician if your symptoms worsen.
Applies to products providing more than 0.42 g of L-Arginine, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you have a cardiovascular disease and are attempting an increase in physical activity (Doutreleau et al. 2010; Doutreleau et al. 2006; Schulman et al. 2006; Goldman and Ausiello 2004; Nagaya et al. 2001; Bednarz et al. 2000; Ceremużyński et al. 1997; Rector et al. 1996).
Sources cited by Health Canada (7)
- Bednarz B, Wolk R, Chamiec T, Herbaczyńska-Cedro K, Winek D, Ceremużyński L. Effects of oral L-arginine supplementation on exercise-induced QT dispersion and exercise tolerance in stable angina pectoris. International Journal of Cardiology 2000;75(2-3):205-210. PubMed Randomised trial
- Ceremużyński L, Chamiec T, Herbaczyńska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. The American Journal of Cardiology 1997;80(3):331-333. PubMed Randomised trial
- Doutreleau S, Rouyer O, Di Marco P, Lonsdorfer E, Richard R, Piquard F, Geny B. L-Arginine supplementation improves exercise capacity after a heart transplant. American Journal of Clinical Nutrition. 2010. Doi: 10.3945/ajcn.2009.27881. DOI
- Doutreleau S, Mettauer B, Piquard F, Rouyer O, Schaefer A, Lonsdorfer J., Beny B. Chronic L-Arginine Supplementation Enhances Endurance Exercise Tolerance in Heart Failure Patients. International Journal of Sports Medicine 2006;27(7):567-572. PubMed
- Nagaya N, Uematsu M, Oya H, Sato N, Sakamaki F, Kyotani S, Ueno K, Nakanishi N, Yamagishi M, Miyatake K. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine 2001;163(4):887-891. PubMed Randomised trial
- Rector TS, Bank AJ, Mullen KA, Tschumperlin LK, Sih R, Pillai K, Kubo SH. Randomized, double-blind, placebo-controlled study of supplemental oral –arginine in patients with heart failure. Circulation 1996;93(12):2135-2141. PubMed Randomised trial
- Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, Hare JM, Gerstenblith G. L-Arginine therapy in acute myocardial infarction: the vascular interaction with age in myocardial infarction (VINTAGE MI) randomised clinical trial. Journal of American Medical Association 2006;295(1):58-64. PubMed Randomised trial
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are taking medication for cardiovascular diseases, erectile dysfunction, and/or blood thinners (Huynh et al. 2002; Parker et al. 2002; Siani et al. 2000; Adams et al. 1995).
Sources cited by Health Canada (4)
- Adams MR, Forsyth CJ, Jessup W, Robinson J, Celermajer DS. Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. Journal of the American College of Cardiology 1995;26(4):1054-1061. PubMed Randomised trial
- Huynh NT, Tayek JA. Oral arginine reduces systemic blood pressure in type 2 diabetes: Its potential role in nitric oxide generation. American College of Nutrition 2002;21(5):422-427. PubMed Clinical trial
- Parker JO, Parker JD, Caldwell RW, Farrell B, Kaesemeyer WH. The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy. Journal of the American College of Cardiology 2002;39(7):1199-1203. PubMed Randomised trial
- Siani A, Pagano E, Iacone R, Iacoviello L, Scopacasa F, Strazzullo P. Blood pressure and metabolic changes during dietary L-arginine supplementation in humans. American Journal of Hypertension 2000;13(5):547-551. PubMed Randomised trial
Contraindications
Applies to products providing more than 9 g of L-Arginine, per day.
Do not use if you have had a heart attack/myocardial infarction (Sun et al. 2009; Schulman et al. 2006; Bednarz et al. 2005).
Sources cited by Health Canada (3)
- Bednarz B, Jaxa-Chamiec T, Maciejewski P, Szpajer M, Janik K, Gniot J, Kawka-Urbanek T, Drozdowska D, Gessek J, Laskowski H. Efficacy and safety of oral L-arginine in acute myocardial infarction. Results of the multicenter, randomized, double-blind, placebo-controlled ARAMI pilot trial. Kardiol Pol. 2005;62(5):421-427. PubMed Randomised trial
- Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, Hare JM, Gerstenblith G. L-Arginine therapy in acute myocardial infarction: the vascular interaction with age in myocardial infarction (VINTAGE MI) randomised clinical trial. Journal of American Medical Association 2006;295(1):58-64. PubMed Randomised trial
- Sun T, Zhou WB, Luo XP, Tang YL, Shi HM. Oral L-arginine supplementation in acute myocardial infarction therapy: a meta-analysis of randomized controlled trials. Clin Cardiol. 2009;32(11):649-652. PubMed Meta-analysis
Known adverse reactions
Applies to products providing more than 9 g of L-Arginine, per day.
When using this product you may experience gastrointestinal discomfort/disturbances (Grimble 2007; Evans et al. 2004; IOM 2005; Clarkson et al. 1996).
Sources cited by Health Canada (4)
- Clarkson P, Adams MR, Powe AJ, Donald AE, McCredie R, Robinson J, McCarthy SN, Keech A, Celermajer DS, Deanfield JE. Oral L-arginine endothelium-dependent dilation in hypercholesterolemic young adults. Journal of Clinical Investigation 1996;97(8):1989-1994. PubMed Randomised trial
- Evans WR, Fernstrom JD, Thompson J, Morris SM Jr, Kuller LH. Biochemical responses of healthy subjects during dietary supplementation with L-arginine. Journal of Nutritional Biochemistry 2004;15(9):534-539. PubMed
- Grimble GK. Adverse gastrointestinal effects of arginine and related amino acids. The Journal of Nutrition 2007;137(6 Suppl 2):1693S-1701S. PubMed Review article
- IOM 2005: Institute of Medicine. Panel on Dietary Reference Intakes for Electrolytes and Water, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate. Washington (DC): National Academies Press; 2005.
- quercétine
Read the warning, when it applies and the studies cited
QUERCETIN
Route of administration: Oral
Cautions and warnings
Applies to products providing 40 milligrams or more Quercetin, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
- Ubiquinone
Read the warning, when it applies and the studies cited
Coenzyme Q10 (UBIQUINONE-10)
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).
Sources cited by Health Canada (2)
- Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
- Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial
Applies to products providing more than 100 mg of Coenzyme Q10 per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).
Sources cited by Health Canada (3)
- Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
- Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
- Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report
Condition of application: Migraine prophylaxis/prevention.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.
- Lysine
Read the warning, when it applies and the studies cited
LYSINE
Route of administration: Oral
Cautions and warnings
Applies to products providing more than 300 mg of lysine, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Goldman and Ausiello 2004).
Sources cited by Health Canada (1)
- Goldman L, Ausiello D, editors. Cecil Textbook of Medicine, Volume 1, 22nd edition. Philadelphia (PA): Saunders; 2004.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Coriase Hair & Vital: composition and regulation”, https://compoatlas.com/en/supplements/products/5241-coriase-hair-vital, updated 15 November 2026.